Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.
David Avigan(Beth Israel Deaconess Medical Center), Donald Küfe(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Paul G. Richardson(Harvard University), Nikhil C. Munshi(Dana-Farber Cancer Institute), Claire MacNamara, Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Patricia Forino(Beth Israel Deaconess Medical Center), Baldev Vasir(Beth Israel Deaconess Medical Center), Dilani Dombagoda(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Kenneth B. Miller(Tufts Medical Center), Corrine Lenahan(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute), James D. Levine(Beth Israel Deaconess Medical Center), Joanne Proper(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k